ClinVar Miner

Submissions for variant NM_000527.4(LDLR):c.1222G>A (p.Glu408Lys) (rs137943601)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Integrated Genetics/Laboratory Corporation of America RCV000030125 SCV000052780 pathogenic Familial hypercholesterolemia 1 2011-08-18 criteria provided, single submitter curation Converted during submission to Pathogenic.
Invitae RCV000030125 SCV000285013 pathogenic Familial hypercholesterolemia 1 2016-08-08 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid with lysine at codon 408 of the LDLR protein (p.Glu408Lys). The glutamic acid residue is highly conserved and there is a small physicochemical difference between glutamic acid and lysine. This variant is present in population databases (rs137943601, ExAC 0.002%). This variant has been reported in multiple unrelated individuals and families affected with hypercholesterolemia (PMID: 1301956, 14974088, 17347910, 19843101, 20236128). This variant is also known as FH Algeria-1 or E387K in the literature. ClinVar contains an entry for this variant (Variation ID: 36453). Experimental studies have shown that this missense change is a recycling-defective allele (PMID: 1301956, 21531209). In summary, this variant is rare in population databases, has been observed in many patients with hypercholesterolemia, and has been shown to have a deleterious effect on protein function. For these reasons, this variant has been classified as Pathogenic.
LDLR-LOVD, British Heart Foundation RCV000030125 SCV000295310 likely pathogenic Familial hypercholesterolemia 1 2016-03-25 criteria provided, single submitter literature only
Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge RCV000030125 SCV000322938 likely pathogenic Familial hypercholesterolemia 1 2016-03-01 criteria provided, single submitter research 0/208 non-FH alleles
Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies,APHP, GH Hôpitaux Universitaires Pitié-Salpêtrière / Charles-Foix RCV000030125 SCV000503319 likely pathogenic Familial hypercholesterolemia 1 2016-12-16 criteria provided, single submitter clinical testing subjects mutated among 2600 FH index cases screened = 10 , family members = 5 with co-segregation / FH-Algérie-1/Osaka, <2% LDLR Activity / Software predictions: Conflicting
Molecular Genetics Laboratory,Centre for Cardiovascular Surgery and Transplantation RCV000030125 SCV000540803 likely pathogenic Familial hypercholesterolemia 1 2016-11-05 criteria provided, single submitter clinical testing
U4M - Lille University & CHRU Lille, Université de Lille - CHRU de Lille RCV000030125 SCV000583809 pathogenic Familial hypercholesterolemia 1 2017-03-30 criteria provided, single submitter clinical testing
Fundacion Hipercolesterolemia Familiar RCV000030125 SCV000607577 likely pathogenic Familial hypercholesterolemia 1 2016-03-01 criteria provided, single submitter research
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000844747 SCV000711398 likely pathogenic Familial hypercholesterolemia - homozygous 2017-12-08 criteria provided, single submitter clinical testing The p.Glu408Lys variant in LDLR (also described as p.Glu387Lys in the literature ), has been reported in one individual with early myocardial infarction (Do 2015 ) and at least 7 individuals with familial hypercholesterolemia (FH), including at least 3 heterozygotes, 3 homozygotes and 1 compound heterozygote with a secon d pathogenic variant in the LDLR gene (Hobbs 1992, Dedoussis 2004, Widhalm 2007, Taylor 2010). Other clinical laboratories have also reported this variant in Cl inVar (Variation ID 36453). In vitro functional studies provide some evidence t hat the p.Glu408Lys variant may impact ligand recycling as it failed to release ligands in the endosome (Hobbs 1992, Strom 2011). This variant has also been ide ntified in 2/111530 European chromosomes by the Genome Aggregation Database (Gno mAD,; dbSNP rs137943601). This frequency is low enough to be consistent with the frequency of FH in the general population. Add itionally, other amino acid changes at this position have been reported in indiv iduals with FH (Palcoux 2008, Duscova 2011), suggesting that changes at this pos ition may not be tolerated. In summary, although additional studies are required to fully establish its clinical significance, the p.Glu408Lys variant is likely pathogenic. ACMG/AMP Criteria applied: PS4_moderate, PM2, PS3_supporting, PM5_s upporting (Richards 2015).
CSER _CC_NCGL, University of Washington RCV000148564 SCV000190277 likely benign Hypercholesterolaemia 2014-06-01 no assertion criteria provided research
Cardiovascular Genetics Laboratory,PathWest Laboratory Medicine WA - Fiona Stanley Hospital RCV000030125 SCV000268606 pathogenic Familial hypercholesterolemia 1 2011-08-25 no assertion criteria provided clinical testing
Laboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde,Academisch Medisch Centrum RCV000030125 SCV000606366 pathogenic Familial hypercholesterolemia 1 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.